-
Michael Haller, MD, discusses inhaled insulin and Afrezza data for type 1 diabetes
08 Aug 2025 00:54 GMT
… -label, unfortunately."
References:
MannKind Corporation reports second quarter 2025 … results and provides business update. MannKind Corporation. Press release. August … in children with type 1 diabetes. American Diabetes Association. Press release. June …
-
MannKind Corporation (NASDAQ:MNKD) Q2 2025 Earnings Call Transcript
07 Aug 2025 14:01 GMT
… . Joining us today from MannKind are Chief Executive Officer, … well as children’s for diabetes as well as ad … potential in areas like gestational diabetes, inhale first being a … now disconnect.
Follow Mannkind Corp (NASDAQ:MNKD) Follow Mannkind Corp (NASDAQ: …
-
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
06 Aug 2025 21:49 GMT
… , and general corporate purposes,” MannKind CEO Michael Castagna said.
On … type 1 or type 2 diabetes. The company is now … at the mutual agreement of MannKind and Blackstone.
MNKD stock … company over a loan.
MannKind on Wednesday reported Q2 revenues …
-
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
06 Aug 2025 11:10 GMT
… payments during the term. About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses … burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung … AFREZZA and MANNKIND are registered trademarks of MannKind Corporation.
For MannKind:
Investor …
-
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
06 Aug 2025 11:05 GMT
… meaningful milestone for MannKind and people living with diabetes,” said Michael … Castagna, PharmD, Chief Executive Officer of MannKind … for approximately 90 days. About MannKind MannKind Corporation (Nasdaq: MNKD) focuses …
-
Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results
06 Aug 2025 09:23 GMT
… adults with type 2 diabetes and established atherosclerotic cardiovascular disease … director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
30 Jul 2025 20:05 GMT
… for approximately 90 days. About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on … burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease … Facebook, X or Instagram.
For MannKind:
Investor Relations
Ana Kapor
(818 …
-
Diabetes Dialogue: Updates in Type 1 Diabetes and Pregnancy with Carol Levy, MD
26 Jul 2025 01:07 GMT
… program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Diabetes Dialogue: Upcoming Research on Type 1 Diabetes in Pregnancy with Carol Levy, MD
18 Jul 2025 19:08 GMT
… program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
-
Diabetes Dialogue: BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025
16 Jul 2025 19:48 GMT
… director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … hypercortisolism in patients with refractory diabetes and hypertension, noting that … disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and …
About
© 1995-2025